Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Axsome Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AXSM
Nasdaq
8731
https://www.axsome.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Axsome Therapeutics Inc
15 Most Black States in the US
- Apr 22nd, 2024 1:16 pm
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Apr 15th, 2024 11:00 am
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
- Apr 10th, 2024 11:00 am
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
- Apr 2nd, 2024 2:24 pm
Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)
- Apr 2nd, 2024 4:17 am
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
- Apr 1st, 2024 11:00 am
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
- Mar 27th, 2024 11:44 am
30 Countries with the Lowest Depression Rates
- Mar 26th, 2024 10:24 am
20 Cloudiest Cities in the U.S., Ranked
- Mar 26th, 2024 8:56 am
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Mar 25th, 2024 11:00 am
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Mar 25th, 2024 10:30 am
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
- Mar 23rd, 2024 10:45 am
Axsome Triumphs Over Major Depressive Disorder With Auvelity
- Mar 22nd, 2024 2:00 pm
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
- Mar 20th, 2024 4:12 pm
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Mar 19th, 2024 11:00 am
11 Oversold NASDAQ Stocks To Buy Right Now
- Mar 13th, 2024 7:32 pm
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Mar 5th, 2024 12:00 pm
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
- Feb 27th, 2024 12:00 pm
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
- Feb 26th, 2024 8:04 pm
3 Biotech Stocks to Buy and Hold for the Next 10 Years
- Feb 26th, 2024 1:50 pm
Scroll